Sci Rep:肝雌激素受体α对于调节男性的糖原异常和脂质代谢至关重要!

2017-05-12 MedSci MedSci原创

在动物模型和人类中,雌激素的作用受损与代谢综合征的特征密切相关。近期,一项发表在杂志Sci Rep上的研究旨在评估成年雄性小鼠中,肝脏雌激素作用的破坏是否可以重述代谢综合征的相关表现,以了解表型的基础机制。研究者们发现,17β-雌二醇(E2)抑制肝糖异生基因如磷酸烯醇丙酮酸羧激酶1(Pck-1)和葡萄糖-6-磷酸酶(G6Pase),并且在缺乏肝雌激素受体α(Esr1)(LERKO小鼠)的小鼠中不存

在动物模型和人类中,雌激素的作用受损与代谢综合征的特征密切相关。


近期,一项发表在杂志Sci Rep上的研究旨在评估成年雄性小鼠中,肝脏雌激素作用的破坏是否可以重述代谢综合征的相关表现,以了解表型的基础机制。

研究者们发现,17β-雌二醇(E2)抑制肝糖异生基因如磷酸烯醇丙酮酸羧激酶1(Pck-1)和葡萄糖-6-磷酸酶(G6Pase),并且在缺乏肝雌激素受体α(Esr1)(LERKO小鼠)的小鼠中不存在这种作用。雄性LERKO小鼠显示出肝脏糖原生成活性的升高和空腹高血糖。

此项研究还观察到,雄性LERKO小鼠肝脂质沉积和甘油三酯水平升高,这是由脂肪酸合成酶(Fas)和乙酰辅酶A羧化酶(Acc1)的mRNA水平升高反映的肝脂肪生成增加所引起的。

通过ChIP测定显示雌二醇(E2)诱导ESR1与Pck-1、G6Pase、Fas和Acc1启动子结合。与对照组相比,LERKO小鼠的代谢表型显示基础代谢率和喂养均较低。

此外,LERKO小鼠的呼吸频率显着低于对照组,表明脂质氧化增加。

此项研究表明,肝脏E2/ESR1信号在维持男性糖原异常和脂质代谢中起关键作用。

原始出处:
Qiu S, Vazquez JT, et al. Hepatic estrogen receptor α is critical for regulation of gluconeogenesis and lipid metabolism in males. Sci Rep. 2017 May 10;7(1):1661. doi: 10.1038/s41598-017-01937-4.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=199489, encodeId=05571994897d, content=肝雌激素受体a对于男性的糖原异常的调节。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu May 18 07:26:26 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353383, encodeId=2a1e1353383e6, content=<a href='/topic/show?id=c4d484423fa' target=_blank style='color:#2F92EE;'>#脂质代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84423, encryptionId=c4d484423fa, topicName=脂质代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 14 09:40:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503476, encodeId=157515034e6ef, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sun May 14 09:40:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197607, encodeId=84a619e607d9, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Sat May 13 15:43:29 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197491, encodeId=68e519e49132, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sat May 13 09:42:14 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197275, encodeId=5f2819e27572, content=希望有更多的发现和突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat May 13 00:20:13 CST 2017, time=2017-05-13, status=1, ipAttribution=)]
    2017-05-18 jyzxjiangqin

    肝雌激素受体a对于男性的糖原异常的调节。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=199489, encodeId=05571994897d, content=肝雌激素受体a对于男性的糖原异常的调节。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu May 18 07:26:26 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353383, encodeId=2a1e1353383e6, content=<a href='/topic/show?id=c4d484423fa' target=_blank style='color:#2F92EE;'>#脂质代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84423, encryptionId=c4d484423fa, topicName=脂质代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 14 09:40:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503476, encodeId=157515034e6ef, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sun May 14 09:40:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197607, encodeId=84a619e607d9, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Sat May 13 15:43:29 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197491, encodeId=68e519e49132, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sat May 13 09:42:14 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197275, encodeId=5f2819e27572, content=希望有更多的发现和突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat May 13 00:20:13 CST 2017, time=2017-05-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=199489, encodeId=05571994897d, content=肝雌激素受体a对于男性的糖原异常的调节。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu May 18 07:26:26 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353383, encodeId=2a1e1353383e6, content=<a href='/topic/show?id=c4d484423fa' target=_blank style='color:#2F92EE;'>#脂质代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84423, encryptionId=c4d484423fa, topicName=脂质代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 14 09:40:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503476, encodeId=157515034e6ef, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sun May 14 09:40:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197607, encodeId=84a619e607d9, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Sat May 13 15:43:29 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197491, encodeId=68e519e49132, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sat May 13 09:42:14 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197275, encodeId=5f2819e27572, content=希望有更多的发现和突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat May 13 00:20:13 CST 2017, time=2017-05-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=199489, encodeId=05571994897d, content=肝雌激素受体a对于男性的糖原异常的调节。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu May 18 07:26:26 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353383, encodeId=2a1e1353383e6, content=<a href='/topic/show?id=c4d484423fa' target=_blank style='color:#2F92EE;'>#脂质代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84423, encryptionId=c4d484423fa, topicName=脂质代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 14 09:40:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503476, encodeId=157515034e6ef, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sun May 14 09:40:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197607, encodeId=84a619e607d9, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Sat May 13 15:43:29 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197491, encodeId=68e519e49132, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sat May 13 09:42:14 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197275, encodeId=5f2819e27572, content=希望有更多的发现和突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat May 13 00:20:13 CST 2017, time=2017-05-13, status=1, ipAttribution=)]
    2017-05-13 绛珠草小姐

    学习了,谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=199489, encodeId=05571994897d, content=肝雌激素受体a对于男性的糖原异常的调节。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu May 18 07:26:26 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353383, encodeId=2a1e1353383e6, content=<a href='/topic/show?id=c4d484423fa' target=_blank style='color:#2F92EE;'>#脂质代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84423, encryptionId=c4d484423fa, topicName=脂质代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 14 09:40:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503476, encodeId=157515034e6ef, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sun May 14 09:40:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197607, encodeId=84a619e607d9, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Sat May 13 15:43:29 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197491, encodeId=68e519e49132, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sat May 13 09:42:14 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197275, encodeId=5f2819e27572, content=希望有更多的发现和突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat May 13 00:20:13 CST 2017, time=2017-05-13, status=1, ipAttribution=)]
    2017-05-13 dhzzm

    学习了分享了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=199489, encodeId=05571994897d, content=肝雌激素受体a对于男性的糖原异常的调节。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu May 18 07:26:26 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353383, encodeId=2a1e1353383e6, content=<a href='/topic/show?id=c4d484423fa' target=_blank style='color:#2F92EE;'>#脂质代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84423, encryptionId=c4d484423fa, topicName=脂质代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun May 14 09:40:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503476, encodeId=157515034e6ef, content=<a href='/topic/show?id=59d798e61f0' target=_blank style='color:#2F92EE;'>#雌激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98761, encryptionId=59d798e61f0, topicName=雌激素受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae6c9649886, createdName=surilei, createdTime=Sun May 14 09:40:00 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197607, encodeId=84a619e607d9, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Sat May 13 15:43:29 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197491, encodeId=68e519e49132, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Sat May 13 09:42:14 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197275, encodeId=5f2819e27572, content=希望有更多的发现和突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat May 13 00:20:13 CST 2017, time=2017-05-13, status=1, ipAttribution=)]
    2017-05-13 明天会更好!

    希望有更多的发现和突破!

    0

相关资讯

Science:雌激素受体(ER)阳性乳腺癌抵抗PI3K抑制剂疗法的原因

KMT2D甲基转移酶原本受到PI3K信号通路中的AKT蛋白的抑制,当使用PI3K抑制剂后,AKT的活性下降,从而使KMT2D甲基转移酶的功能上升

JCO:妊娠对乳腺癌的预后影响

       一项研究最新发表于JCO,研究者根据有乳腺癌病史的妇女的雌激素受体(ER)状态,探讨怀孕对于无病生存期(DFS)的影响。         本研究为一项多中心,回顾性队列研究,纳入的患者均为在确诊乳腺癌后的任何时间段怀孕,按患者相似的ER状态,淋巴结状态,辅助治疗,年龄,以及确诊时间,按

PLOS ONE: PR(-)、高Ki-67指数对乳腺癌有预测作用

PLOS one:  PR、Ki-67可作为乳腺癌的预测指标 研究背景:luminalB/Her-2(-)乳腺癌即ER(+)和/或PR(+),Her-2(-),Ki-67≥14%的一种乳腺癌亚型。以往研究表明luminalB型乳腺癌早期复发风险高于luminalA型乳腺癌(1.86倍),并且内分泌治疗敏感性不如luminalA型乳腺癌,对化疗敏感性又不如Her-2型和基底细胞样型(BL

Cell Reports:雌激素受体对男性前列腺很重要!

近日,来自美国的科学家在国际学术期刊Cell Reports在线发表了他们的最新研究进展,他们发现在PTEN缺失诱导的前列腺癌发生过程中,雌激素受体β(ERβ)的表达受到抑制,对于前列腺癌发生起到重要推动作用。   雌激素受体(ER)在上皮细胞生物学和癌症中的作用越来越得到关注,在前列腺中,ERβ表达在上皮细胞,而ERα只限于基底层细胞。虽然之前一些研究表明ERβ缺失与恶性疾病有关,

Cancer Res:重大突破!特殊蛋白或可恢复耐受性乳腺癌对常见疗法的敏感性

乳腺癌是一种常见的女性癌症,而且雌激素受体阳性(ER+)的乳腺癌是一种最为常见的乳腺癌类型,目前用于治疗乳腺癌的药物,比如他莫昔芬和氟维司群都能够阻断雌激素受体,而雌激素受体是雌激素受体阳性的乳腺癌细胞生长所必需的受体,这些疗法治疗乳腺癌的常见问题就是许多最初对疗法有反应的肿瘤会慢慢产生耐受性,从而使得疗法变得不再有效。日前,一项刊登在国际杂志Cancer Research上的研究报告中,来自美国

Nature:雌激素受体可致乳腺癌患者出现耐药性

来自英国的一项新研究显示,部分乳腺癌患者对常用的治疗药物表现出耐药性,其原因是体内的雌激素受体改变了“工作路线”,相应研究成果“Differential oestrogen receptor binding is associated with clinical outcome in breast cancer,”发表在新一期的英国《自然》Nature杂志网络版上。 雌激素受体是一种能与基因